📦 The deal focuses on manufacturing antibody therapeutics.
🧬 Ottimo is developing Jankistomig, targeting cancer pathways.
🏭 LOTTE will produce at its New York Bio Campus.
🚀 This partnership boosts efficiency in drug development.
🌍 LOTTE aims to expand its capabilities globally by 2027.
Introduction:
The recent contract manufacturing agreement between South Korea-based LOTTE BIOLOGICS and Ottimo Pharma marks a significant collaboration in the biopharmaceutical industry, focusing on the production of antibody therapeutics aimed at combating cancer. This partnership underscores the growing importance of contract development and manufacturing organizations (CDMOs) in the development of innovative therapies.
- LOTTE BIOLOGICS has signed a contract manufacturing agreement with Ottimo Pharma for the production of PD1/VEGFR2 dual pathway antibodies.
- The manufacturing will take place at LOTTE’s Syracuse Bio Campus in New York, enhancing Ottimo’s capability to advance its product Jankistomig.
- LOTTE’s CEO, James Park, emphasized the agreement’s validation of LOTTE’s competitiveness in the global antibody therapeutics market.
- Ottimo Pharma’s Vice President Joseph Shultz highlighted that this partnership will facilitate their operational readiness for IND submission and clinical trials.
- LOTTE also plans to expand its operations with a new large-scale manufacturing facility in Songdo, South Korea, expected to commence in 2027, which will support major global contracts.
Conclusion:
This collaboration between LOTTE BIOLOGICS and Ottimo Pharma not only underscores the business dynamics within the biopharmaceutical sector but also signals a commitment to advancing cancer therapeutics through efficient manufacturing solutions. As the industry evolves, such strategic partnerships are likely to play a crucial role in facilitating timely drug development and enhancing patient outcomes.
